focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hardman & Co
The demerger of Haleon has had little benefit on a more-focused GSK. Just after the demerger, the company was hit by the filing of litigation in the US claiming a causal association between ranitidine (Zantac) therapy and the development of cancer. In our opinion, there was little to support these claims, especially given the successful patient outcomes after billions of uses of the drug since launch. In 2023, GSK made a modest out-of-court settlement, but this did not trigger a re-rating back to the level seen prior to the claims first being made. At the end of the year, management indicated that it was going to embark on significant M&A activity in 2024, but this is expected to be in the form of licensing in drugs, rather than company takeovers, because of its current level of indebtedness. It will be interesting to see what the company does
Moderna’s shares were falling after the biotech revealed data that might hurt its vaccines competitive position.
In a note that appears to have shaken investor confidence in the product on Thursday TD Cowen analyst Tyler Van Buren wrote the data suggests the efficacy of Moderna’s RSV vaccine may fall off more quickly over time than those of its competitors.
It “could negatively affect mRNA-1345’s profile if confirmed with additional data” Van Buren wrote.
Moderna’s shares dropped 5.7% on Thursday and were down another 6.4% Friday.
Holding on for that sweet 17 before I finally say goodbye to the lion's share of my GSK holding. Here's hoping we hit that target pretty soon. All things considered it finally seems possible.
Sold opportunistically today. Return was good enough since buying after the drop in August 2022.
Multiple RNSs landing.
£20 here we come within 6 months?
All IMHO DYOR
Happy
Is this share waking up at last ?
I've held for the best part of 30 years and I can't remember the SP being higher than what I paid.
If it is, it's about time !
Sometimes you just need to hold and wait. Propping up my portfolio this year... More to come.
Well done go all LTH
Who would want to be out of this on the 22nd for ex dividend date and secure another 16p...
Point taken but it's not difficult to be despondent with GSK. Minus 3% tomorrow would not surprise me..........
So you stick with a share for years then just as it gets any momentum you sell? IMO madness. There’s been nothing but good news for a while, that will take time to feed in to the results. If they can get past the litigation, I can’t see much holding gsk back from at least getting to parity with its peers.
52 week high £16.70. Looking at my shares after the HLN split with dividends it's finally looking a bit more promising. Get to even and run away.....
Just in case you missed it :_
Deutsche Bank raises GSK price target to 1,950 (1,850) pence - 'buy'
....this will be new floor!
NervousNelly, we are grateful that you read your tea leaves this morning, though it is a pity, those same tea leaves, failed to advise you that you would go in the GSK, site instead of your normal LGEN, site. Unfortunately, you failed to provide, any words of wisdom on the GSK, equity, which is just as well because LGEN, fundamentals, would not be relevant.
No matter what the word is on people who go by charts etc. With GSK settling the Zantac claim out of court with no claim of liability this has got to be good news for us long termers. I've already put my money where my mouth is this morning and added to my holding. GLA
As expected the sp, retraced with profit taking at 1600 level, which is where the long term upward sloping resistance line is situated . The recent Bollinger band high of 1631, was not breached, and the equity is falling back to the region of yesterday's Bollinger band high. Long term support for GSK, is situated at the up sloping trend line at 1500. DYOR.
Looks like others on the zoom were impressed. I’m very happy with my top up this morning. The fall was unwarranted, surprised that it changed round intraday but it doesn’t really matter as these are a long term hold. The market should start to appreciate gsk at some point and I will be here when it does.
[GSK] I joined the Zoom call at 11.00 to see if I could detect anything in the fundamentals that would justify the initial fall in share price. I couldn't. The full year figures were good but were expected to be; what was new was the rise in the sales, profit and eps growth in the period 2026 - 31. They expect 12 new product launches in this period and that margins will remain "stable" despite loss of patent protection on some drugs. What came out was that these are "risk adjusted" (kept modest) projections. They did show a non risk adjusted growth projection which phenomenal. With debt coming down, growth going up and margins not deteriorating I broke my usual rules and increased my holding at 1534p during the meeting. This stock is cheap relative to other pharmaceutical companies and doing well in a couple of well defined niches, yes, I know Zantac overshadows the company but with free cash flow of over £3.4b per year would they not survive if the drug was proved to have a very low rate of carcinogenesis? I see the stock is going up post the meeting so Romeike you may yet see your £18 - 20 level.
Because there was a run up ahead of results in anticipation they would be good. Some of those are now profit taking on their call and closing long contracts. I'm expecting a move back up towards 18-20 level once the news from Delaware is out.
I’m going to keep buying. In comparison to its peers gsk is undervalued. Nothing to warrant a drop today.
So unloved, don’t understand.
Can't believe we're down after that update. Same reaction as the last good update!
ZANTAC , Liability???
What didn’t market like?
July 12th this year!